Inotersen Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

The US Food and Drug Administration (FDA) has approved inotersen (TEGSEDI) for the treatment of adults with e polyneuropathy of hereditary transthyretin-mediated amyloidosis.
 

Stay informed on the latest rare disease news and developments by signing up for our newsletter.

Let's block ads! (Why?)

https://www.raredr.com/news/inotersen-approved-polyneuropathy-hereditary-transthyretinmediated-amyloidosishttps://desimpul.blogspot.com/2018/10/inotersen-approved-for-polyneuropathy.html